Clinical Characteristics and Outcomes of Hypersensitivity Pneumonitis: A Population-Based Study in China
Hypersensitivity pneumonitis (HP), also known as extrinsic allergic alveolitis, is a complex interstitial lung disease caused by an exaggerated immune response to inhaled organic or inorganic antigens. It is characterized by inflammation and fibrosis of the lung parenchyma, leading to significant morbidity and mortality. Despite its global prevalence, there is a paucity of population-based studies on HP in China, making it challenging to understand the disease’s clinical characteristics and outcomes in this region. This study aims to fill this gap by providing a comprehensive analysis of HP in a Chinese population.
The study was conducted at Nanjing Drum Tower Hospital, a major tertiary care center in Nanjing, China. The authors retrospectively analyzed the medical records of patients diagnosed with HP between January 2010 and December 2018. The diagnosis of HP was based on a combination of clinical, radiological, and histopathological criteria, as outlined by the American Thoracic Society and European Respiratory Society guidelines. Patients with incomplete data or alternative diagnoses were excluded from the study.
A total of 152 patients were included in the analysis. The mean age of the cohort was 54.3 years, with a slight female predominance (56.6%). The most common presenting symptoms were dyspnea (89.5%), cough (78.9%), and fever (45.4%). The majority of patients (72.4%) had a history of exposure to known HP antigens, with bird antigens being the most prevalent (38.2%), followed by mold (24.3%) and agricultural dust (9.9%).
Radiological findings were consistent with HP in all patients. High-resolution computed tomography (HRCT) scans revealed ground-glass opacities in 92.1% of cases, mosaic attenuation in 76.3%, and fibrosis in 43.4%. Histopathological examination, performed in 45 patients, showed features of chronic interstitial inflammation, granulomas, and fibrosis, further supporting the diagnosis.
Pulmonary function tests (PFTs) were available for 128 patients. The most common abnormality was a restrictive pattern, observed in 68.8% of cases, followed by a mixed restrictive and obstructive pattern in 21.1%. Diffusing capacity of the lungs for carbon monoxide (DLCO) was reduced in 76.6% of patients, indicating impaired gas exchange.
The study also evaluated the treatment and outcomes of HP. The majority of patients (84.2%) received corticosteroids as the primary treatment, with or without additional immunosuppressive agents. Antigen avoidance was recommended to all patients, and 64.5% reported successful avoidance. The mean follow-up period was 36.7 months, during which 22.4% of patients experienced disease progression, defined as a decline in lung function or worsening of symptoms. The overall mortality rate was 14.5%, with respiratory failure being the leading cause of death (62.5%).
Several factors were associated with poor outcomes, including older age, presence of fibrosis on HRCT, and reduced DLCO at diagnosis. Multivariate analysis identified fibrosis on HRCT as an independent predictor of mortality, with a hazard ratio of 3.12.
The study also highlighted the challenges in diagnosing HP, particularly in differentiating it from other interstitial lung diseases such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP). The authors emphasized the importance of a multidisciplinary approach, involving pulmonologists, radiologists, and pathologists, to improve diagnostic accuracy.
In conclusion, this population-based study provides valuable insights into the clinical characteristics and outcomes of HP in China. The findings underscore the importance of early diagnosis, antigen avoidance, and appropriate treatment to improve patient outcomes. The study also highlights the need for further research to better understand the pathogenesis of HP and to develop targeted therapies for this debilitating disease.
doi.org/10.1097/CM9.0000000000001158
Was this helpful?
0 / 0